Efficacy and Safety of a 1726-nm Sebaceous-Targeting Diode Laser for the Treatment of Fordyce Spots of the Lips: A Prospective Pilot Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Percentage Reduction in Fordyce Spot Count
研究概览
简要总结
Fordyce spots are benign ectopic sebaceous glands commonly affecting the lips and vermilion border, often causing cosmetic concern. This prospective pilot study evaluates the efficacy and safety of a 1726-nm sebaceous-targeting diode laser (Accure®) for the cosmetic treatment of Fordyce spots of the lips. Participants will receive 2-3 laser sessions and will be followed for 6-12 months to assess clinical improvement, patient satisfaction, and safety outcomes.
详细描述
This is a prospective, single-arm pilot study evaluating the use of a 1726-nm diode laser that selectively targets sebaceous glands via lipid absorption. The device employs a temperature-guided, multi-pulse delivery system with continuous cooling and is FDA-cleared for the treatment of inflammatory acne.
Eligible participants with clinically evident Fordyce spots of the lips and/or vermilion border will receive 2-3 treatment sessions spaced four weeks apart. Outcomes include lesion count reduction, global aesthetic improvement scores, patient satisfaction, and safety assessments. Follow-up visits will occur at Weeks 4, 8, 12, 24. To better characterize durability and recurrence, participants will be invited (optional) to return for an additional observational follow-up at Month 12 (±4 weeks), without any additional study treatment. Participants who do not attend the Month-12 visit will be considered complete after the Week-24 assessment and will not be contacted further beyond routine clinical care. All analyses of efficacy and safety will be based on assessments through Week 24, with Month-12 data summarized descriptively as extended follow-up where available.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years
- •Clinically evident Fordyce spots involving: Upper and/or lower lips and/or vermilion border
- •Cosmetic concern related to Fordyce spots
- •Willingness to comply with study procedures and follow-up visits
- •Ability to provide written informed consent
排除标准
- •Active herpes labialis at the treatment site
- •History of frequent HSV reactivation without willingness for antiviral prophylaxis
- •Isotretinoin use within the preceding 6 months
- •Active inflammatory or infectious lip/mucosal disease (e.g., lichen planus, cheilitis, candidiasis)
- •Known tendency for keloid or hypertrophic scarring Pregnancy or lactation
- •Immunosuppression or uncontrolled systemic illness
- •Previous treatment of Fordyce spots in the target area within 3 months
结局指标
主要结局
Percentage Reduction in Fordyce Spot Count
时间窗: Baseline to Week 12
The percentage change from baseline in the number of visible Fordyce spots on the lips and vermilion border, assessed using standardized clinical photographs and lesion counting within predefined grid areas.
次要结局
- Treatment Safety and Tolerability(Baseline to Month 6)
- Investigator Global Improvement Assessment (IGA)(Baseline to Week 12)
- Patient Global Aesthetic Improvement Scale (Patient-GAIS)(Baseline to Week 12)
- Patient Satisfaction Score(Week 12)
研究者
Mahmoud Rageh
Dermatologist
Venus Research Center
